Table 3. Comparison of the clinical data of patients with and without ocular cGvHD following HSCT.
| HSCT patients without ocular cGvHD (n=9) (1st quartile / median / 4th quartile) | HSCT patients with ocular cGvHD (n=18) (1st quartile / median / 4th quartile) | Level of significance (Wilcoxon test) | |
|---|---|---|---|
| Schirmer test |
0/2/4 |
0/0/0.5 |
p=0.07 |
| OSDI |
31/51/56 |
43/54/77 |
p=0.15 |
| Break-up time |
2/3/4 |
3/3.5/4 |
p=0.52 |
| Sex (female) |
56% (5) |
28% (5) |
p=0.15 |
| Age (years) |
46/55/56 |
48/53/62 |
p=0.88 |
| Oxford grading scale |
1/2/3 |
2/3/4 |
p=0.04 |
| Blinking rate=elevated with blepharospasm |
78% (7) |
100% (18) |
p=0.03 |
| % HLA-DR expression |
13/29/44 |
22/28/41 |
p=0.88 |
| CD8 |
11% (1) |
22% (5) |
0.484 |
| Systemic immunosuppression |
67% |
33% |
p=0.31 |
| Conjunctival scar |
33% |
83% |
<0.05 |
| cGvHD skin | 89% | 78% | p=0.48 |
Comparison of the clinical data of patients with (n=18) and without (n=9) chronic ocular graft versus host disease (cGvHD) following hematopoietic stem cell transplantation: Statistical differences were found for Oxford grades, blinking rates and conjunctival scarring. 4 out of 5 patients with conjunctival cluster of differentiation (CD)8 positive lymphocytes suffered from ocular cGvhD.